StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) income statement

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.59−0.19 (-10.67%)

Close on Nov 18, 2026Market cap $52.03MP/E –Yield –

Insight Molecular Diagnostics Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
48.3%
Operating margin
-3011.9%
Net margin
-2955.6%
Return on equity, FY2025
229.6%

Financial strength

Current ratio
2.00
Debt to equity
–
Debt to assets
–
Cash to current liabilities
172.6%

Valuation

P/E ratio
–
Price to sales
31.16
Price to book
–
Dividend yield
–

See a number that looks wrong?